Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles

New stock news | New Lotus Flower Delivers Table Hong Kong Stock Exchange, company is China's leading supplier of traditional Chinese medicine products, ranked second in the traditional Chinese medicine industry

New Stock News | Minglue Technology-W Attends Hearing in Hong Kong Stock Exchange, Company is China's largest supplier of data intelligence application software.

Shenwan Hongyuan Group: Transitioning from a style of "buying high and selling low" in A shares, but with different offensive and defensive strategies.
New stock news | New Lotus Flower Delivers Table Hong Kong Stock Exchange, company is China's leading supplier of traditional Chinese medicine products, ranked second in the traditional Chinese medicine industry

New Stock News | Minglue Technology-W Attends Hearing in Hong Kong Stock Exchange, Company is China's largest supplier of data intelligence application software.

Shenwan Hongyuan Group: Transitioning from a style of "buying high and selling low" in A shares, but with different offensive and defensive strategies.

RECOMMEND